A First in Human Phase 1 Open-Label, Multicenter, Dose Escalation and Expansion Study of DEG6498 in Patients With Solid Tumors
Latest Information Update: 17 Dec 2025
At a glance
- Drugs DEG 6498 (Primary)
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Degron Therapeutics
Most Recent Events
- 08 Dec 2025 Status changed from not yet recruiting to recruiting.
- 01 Dec 2025 New trial record